NCT05008055已完成2 期
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
详细描述
The study protocol follows a modular design. The study will investigate the safety and efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be ≥ 18 years of age, at the time of signing the informed consent
- •Eastern Cooperative Oncology Group performance status ≤ 2
- •Life expectancy > 6 months
- •Female participants must not be breast-feeding and must have a negative pregnancy test (serum) prior to start of dosing
- •Module 1 specific inclusion criteria:
- •Additional Inclusion Criteria for Cohort 1A (R/R FL):
- •Histologically confirmed diagnosis of FL Grade 1, 2, or 3a as assessed by investigator or local pathologist
- •Current need for systemic treatment based on the Investigator's opinion
- •Relapsed, progressed or refractory (defined as failure to achieve at least a partial response [PR]) after at least 2 prior systemic lines of therapy (including anti-CD20 monoclonal antibody [mAb] and an alkylating agent)
- •Bi-dimensionally measurable disease on cross sectional imaging by computed tomography (CT) or magnetic resonance imaging (MRI) with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis.
- •Additional Inclusion Criteria for Cohort 1B (R/R MZL):
- •Histologically confirmed MZL including splenic, nodal, and extranodal subtypes as assessed by investigator or local pathologist
- •Current need for systemic treatment based on the Investigator's opinion
- •Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy (including at least one anti-CD20mAb directed regimen either as monotherapy or as chemoimmunotherapy; Helicobacter pylori eradication and radiation therapy alone will not be considered a systemic treatment regimen)
- •Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis
- •Additional Inclusion Criteria for Cohort 1C (R/R MCL):
- •Histologically confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1, as assessed by investigator or local pathologist
- •Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy
- •Participants must have received as prior therapies
- •Prior regimens must have included:
- •BTK inhibitor and
- •Anti-CD20mAb therapy
- •Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis
排除标准
- •Prior malignancy (other than the disease under study), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the participant has been disease free for ≥ 2 years
- •With the exception of alopecia, any unresolved non-haematological toxicities from prior therapy ≥ Common Terminology Criteria for Adverse Events Grade 2 at the time of starting study treatment
- •Known medically apparent central nervous system lymphoma or leptomeningeal disease
- •Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values at screening:
- •Absolute neutrophil count < 1.0 × 10^9/L; < 0.75 × 10^9/L in participants with known bone marrow involvement of malignant disease
- •Platelets < 75 × 10^9/L; < 50 × 10^9/L in participants with known bone marrow involvement of malignant disease
- •Creatinine clearance < 50 mL/min per the Cockcroft and Gault formula
- •Clinically significant abnormalities of glucose metabolism as participants with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment and Glycosylated haemoglobin ≥ 8.0% (63.9 mmol/mol)
- •Prior treatment with any of the following:
- •Any investigational agents or study drugs from a previous clinical study within 5 half lives or 2 weeks from the first dose of capivasertib in this study
- •Strong inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to inhibition of CYP3A4 within 1 week prior to the first dose of study treatment
- •Prior allogenic Haematopoietic stem cell transplant (HSCT) within 6 months from the first dose of capivasertib (patients > 6 months after allogenic HSCT are eligible in the absence of active graft-versus-host disease and concomitant immune suppressive therapy). Prior cellular therapies (eg, Chimeric antigen receptor T therapy) and/or autologous HSCT within 3 months from the first dose of capivasertib
- •Receipt of live, attenuated vaccine within 28 days before the first dose of study treatment(s)
- •Participants who, due to other medical conditions /prior history /concomitant medications are, in the investigator's opinion, at a risk of a venous thromboembolism (VTE) and are not willing to accept the VTE prophylaxis, will be excluded. The initiation of an adequate VTE prophylaxis will be based on treating physician risk/benefit assessment and in agreement with the local management guidelines
- •Additional exclusion core criteria may apply, please refer to the protocol
- •Module 1 specific exclusion criteria:
- •Follicular lymphoma grade 3B
- •Known transformation to aggressive lymphoma, eg, large cell lymphoma
- •Participants who, in the Investigator's opinion, require immediate cytoreductive therapy for disease control
研究组 & 干预措施
Capivasertib monotherapy
Experimental
Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
干预措施: Capivasertib (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: First dose until progression of disease [PD] or last evaluable assessment in the absence of progression or data cut-off date (21.6 Months)
Objective response rate is defined as the proportion of patients achieving either complete response (CR) or partial response (PR) according to the Lugano 2014 Classification for non-Hodgkin lymphoma (NHL) as assessed by blinded independent central review (BICR).
次要结局
- Duration of Response(First documented response until date of documented progression or data-cut off date (21.6 Months))
- Progression-free Survival(First dose until documented disease progression or data cut-off date (21.6 Months))
- Overall Survival (OS)(First dose until data cut-off date (21.6 Months))
- Number of Patients With Adverse Events and Serious Adverse Events(Screening (Day -28 to -1) until Post-treatment follow-up up to 30 days after last dose or long-term follow-up or study completion (Every 12 weeks until death or lost to follow-up, unless patient have withdrawn consent [up to 21.6 Months]))
- Plasma Concentration of Capivasertib Overtime(Cycle 1 (28-day treatment Cycle) Day 1 and on Cycle 1 Day 8, Cycle 1 Day 15 and Cycle 1 Day 22 (Pre-dose and post-dose))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerCCCA Assessed by Ki67 Drop Below <2.7% From BaselineNCT06607757GBG Forschungs GmbH120
已完成
2 期
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast CancerBreast CancerNCT02846428Hoffmann-La Roche182
终止
2 期
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600EMalignant MelanomaNCT01586195Genentech, Inc.31
招募中
1 期
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerPancreatic CancerNCT05827796InxMed (Shanghai) Co., Ltd.70
已完成
2 期
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaMultiple MyelomaNCT03601078Celgene312